LigaChem Biosciences
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
LigaChem Biosciences develops cancer-fighting drugs that work by attaching a toxic payload directly to an antibody, which then seeks out and targets tumor cells, a class of medicines known as antibody-drug conjugates, or ADCs.
The company also researches synthetic small-molecule drugs, including treatments for antibiotic-resistant bacterial infections, and supplies medical consumables and devices to hospitals. Listed on KOSDAQ, Korea's tech-focused stock exchange, it operates primarily as a drug-discovery and technology-licensing business, generating revenue by out-licensing its proprietary ADC platform, called ConjuALL, to global pharmaceutical companies.
Summary is AI-generated and may contain errors · figures from DART filings
The company has licensed its ConjuALL ADC platform technology to multiple global pharmaceutical companies and has received the Best ADC Platform Technology award at the World ADC Awards on several occasions.
LigaChem Biosciences in five facts
What does LigaChem Biosciences do?
LigaChem Biosciences develops cancer-fighting drugs that work by attaching a toxic payload directly to an antibody, which then seeks out and targets tumor cells, a class of medicines known as antibody-drug conjugates, or ADCs.
Where is LigaChem Biosciences listed and in which sector?
LigaChem Biosciences (Korean name: 리가켐바이오) trades under KRX code 141080 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is LigaChem Biosciences?
Its market capitalisation was US$2B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were LigaChem Biosciences's latest annual revenue and operating profit?
For fiscal year 2025, LigaChem Biosciences reported revenue of US$106.8M, an operating loss of US$80.4M and a net loss of US$69.1M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 12.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (abbreviated)Oct 2
- Material management matter relevant to investment decisionsSep 30
- Investor relations (IR) meetingSep 8
- [quarterly, individual company] Large business group status disclosureAug 31
- [Amended] Material event report (rights offering)
LigaChem Biosciences updated the terms of convertible bonds to raise US$224M, about 10.7% of its market value.
Capital raise · Jul 22 - [Amended] Material event report (convertible bonds)
LigaChem Biosciences updated the terms of convertible bonds to raise US$115M, about 5.5% of its market value.
Capital raise · Jul 22 - [Amended] Material event report (convertible bonds)
LigaChem Biosciences updated the terms of convertible bonds to raise US$115M, about 5.5% of its market value.
Capital raise · Jul 16 - [Amended] Material event report (rights offering)
LigaChem Biosciences updated the terms of convertible bonds to raise US$0.22K, about 0.0% of its market value.
Capital raise · Jul 16 - Material event report (rights offering)
LigaChem Biosciences disclosed convertible bonds to raise US$213M, about 10.7% of its market value.
Capital raise · Jun 26 - Material event report (convertible bonds)
LigaChem Biosciences disclosed convertible bonds to raise US$110M, about 5.5% of its market value.
Capital raise · Jun 26 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
LigaChem Biosciences reported consolidated results for FY2025: revenue of US$98.2M (+12.4% year on year), an operating loss of US$73.9M and a net loss of US$63.5M (from a profit a year earlier).
Earnings · Feb 13